We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.
- Authors
Watanabe, Sumio; Enomoto, Nobuyuki; Koike, Kazuhiko; Izumi, Namiki; Takikawa, Hajime; Hashimoto, Etsuko; Moriyasu, Fuminori; Kumada, Hiromitsu; Imawari, Michio
- Abstract
Aim: This study was conducted to clarify the factors related to sustained virological response (SVR) to pegylated interferon α 2b (PEG-IFN) plus ribavirin (RBV) combination therapy administered for 48 weeks in patients with chronic hepatitis C virus (CHCV) and to evaluate the usefulness of prolonged treatment in patients with late virological response (LVR). Methods: Of 2257 patients registered at 68 institutions, those with genotype 1 and high viral load were selected to participate in two studies. Study 1 (standard 48-week group, n = 1480) investigated SVR-determining factors in patients who received the treatment for ≤52 weeks, whereas study 2 compared SVR rates between patients with LVR who received treatment for either 36–52 weeks (48-week group, n = 223) or 60–76 weeks (72-week group, n = 73). Results: In study 1, SVR rate was 44.9%; that in male subjects (50.4%) was significantly ( P < 0.0001) higher than in female subjects (36.4%). SVR rate significantly ( P < 0.0001) decreased with 10-year age increments in both sexes. Multivariate logistic regression analysis revealed that age, F score, platelet count, and HCV load were SVR-related factors. In study 2, SVR rate in the 72-week group (67.1%) was significantly ( P = 0.0020) higher than in the 48-week group (46.2%). Conclusions: Patients with CHCV genotype 1 infection should be treated with PEG-IFN plus ribavirin combination therapy as early as possible, and 72 weeks' treatment is recommended in patients with LVR regardless of age.
- Subjects
JAPAN; HEPATITIS C treatment; INTERFERONS; RIBAVIRIN; VIROLOGY
- Publication
Hepatology Research, 2010, Vol 40, Issue 2, p135
- ISSN
1386-6346
- Publication type
Article
- DOI
10.1111/j.1872-034X.2009.00567.x